Magnetic labeling of platelets for targeted drug delivery in the personalized therapy field

Abstract

The development of new drug delivery systems is an urgent task today. An administration of micro- and nano-sized containers loaded with a drug reduces the number of side effects on healthy organs. Despite great advances in a field of addressed drug delivery developing, a targeting of drug carriers often remains haphazard. The body has an innate immune defense that quickly recognizes and destroys foreign objects. Thus, nanocarriers can be taken up by macrophages before the carriers reach the region of interest. In addition, toxicity and limited biodegradability is a significant disadvantage for many of these approaches. The main condition for creating a controlled system for targeted drug delivery to target tissues or organs is drug bioavailability and prolonged drug release in the area of interest. In this regard, the use of the patient's blood cells as drug carriers for the treatment of one person allows for individual targeted therapy of diseases, which reduces the risk of unwanted side effects. Developed biological carriers, for example, platelets, are able to bypass the immune barrier, which makes them attractive objects for creating biological systems for targeted drug delivery in the field of personalized therapy.
This study demonstrates successful magnetic labeling of platelets from platelet concentrates with FITC-BSA conjugated FeNP. The ζ-potential (-20.28 ± 1.18 mV) and small size (57.5± 5.0 nm) of FeNP-BSA(FITC) nanosystems had a minor impact on platelet activation ability compared to unprocessed platelets. Platelet internalization was studied using CLSM and flow cytometry. The separation of magnetic platelets was performed using a magnetic separator MACS® Magnetic Separators for cell separation with the study of the separated mixtures by flow cytometry. A differentiation of magnetic platelets activated by tumor cells will allow to detect circulating tumor cells from the body using modern cytological methods of individual therapy for one person. A degree of the platelet activation with trapped FITC-BSA-FeNP by circulating tumor cells and healthy cells both using confocal microscopy and flow cytometry. The mouse skin melanoma cell line B16F10 will be used as metastasizing cells, and the mouse fibroblast cell line L929 will be considered as healthy cells.

This work was supported by the Russian Science foundation (project no. 18-19-00354P).

Speaker

Oksana Mayorova
Saratov State University
Russia

Discussion

Ask question